



Meta-Analysis of the Antioxidant and Antitumor Effects about Resveratrol in Animal Models with Breast Cancer: Integrative Review for Clinical Study Design

Gabriella Trettel Dermondes^{1*}, Maurício Frota Camacho² and Clelia Rejane Antônio Bertoncini³

¹Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil

²Functional Proteomics Laboratory, Institute of Science and Technology, Federal University of Sao Paulo, São José dos Campos, Brazil

³Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil

***Correspondence:** Gabriella Trettel Dermondes, Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil, E-mail: gabriella.trettel@unifesp.br; DOI: <https://doi.org/10.56147/jbhs.2.3.42>

Co-correspondence: Clelia Rejane Antônio Bertoncini, Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil, E-mail: clelia.rejane@unifesp.br

Citation: Dermondes GT, Camacho MF, Bertoncini CRA (2025) Meta-Analysis of the Antioxidant and Antitumor Effects about Resveratrol in Animal Models with Breast Cancer: Integrative Review for Clinical Study Design. J Biol & Heal Sci 2: 42.

Abstract

Natural compounds are promising adjuvants in various treatments, with lowest rate of harmful effects to the organism, greater tolerance and convenience for patients, especially those undergoing longer treatments of chronic diseases. Breast cancer is the type of cancer that most affects women in the world, being the most frequent cause of cancer death between women. Several chemotherapeutic drugs already standardized for cancer treatment originate from components predominantly extracted from plants. The resveratrol, the main grapes polyphenol, has its antioxidant activity well established in the literature, highlighting its potential antitumor effect. The aim of this work was to synthesize, in a quantitative and qualitative means, data on the effect of resveratrol on breast tumorigenesis, based on *in vivo* and clinical studies. We performed a computerized search using the keywords. The selection criteria were given *in vivo* in female rats and mice, comparative experiments of tumor mass before and after treatment with resveratrol, in addition to resveratrol as an adjuvant in synergy with other compounds known in the literature for their antioxidant and/or anti-tumor action. Data collected from studies were structured in spreadsheets and classified according to the substances used, which were distributed into four groups: RSV, RSV+hormone modulators, RSV+antioxidants and RSV+antineoplasics. The percentages were calculated of tumor that remained after the treatment proposed by the study (residual tumor). The results obtained in our meta-analysis in animal models showed that resveratrol has an antineoplastic effect in 85% of studies in female rodents with breast cancer, reaching its highest percentage of antitumor effect with a dosage of 25 mg/kg of resveratrol (reduction tumor rate of 97.8%). Associated with other antioxidants, resveratrol had a synergistic effect on tumor reduction (86.01%), as well as when associated with hormonal modulators (58.33%) and antineoplastic drugs (91%), in addition to having its action potentiated when used together with radiation therapy (89% tumor reduction). Data from clinical studies have shown a reduction in breast tumorigenesis through its already known mechanisms of action, such as selective apoptosis, inhibitors of cell proliferation and inflammatory mediators, in addition to hormonal regulation. Therefore, our statistical and qualitative results showed resveratrol as a potential agent in the prevention or adjuvant treatment of female breast cancer, generally amplifying the antitumor effects when combined with standard treatment.

Keywords: Resveratrol; Apoptosis; Breast cancer; Meta-analysis; Oxidative stress

Received date: May 19, 2025; **Accepted date:** May 24, 2025; **Published date:** June 09, 2025



Introduction

The occurrence of cancer is of multifactorial origin and encompasses the combination of different genetic and environmental factors such as eating habits, weight, smoking, physical inactivity, alcohol, exposure to contaminating factors, random genetic mutations, among others. The synergism between these characteristics increases the risk of both cancer and other diseases, with primary prevention, with behavioral habits from the early stages of life, being the most effective way to significantly reduce harmful patterns to the body in general [1-4].

Biological capabilities acquired during the multiple steps of tumor development include mutation and genomic instability, self-sufficiency in growth factors associated with cell proliferation, resistance to inhibitory growth control mechanisms and resistance to apoptosis (programmed cell death). Furthermore, tumor cells are characterized by unlimited potential for proliferation and replication, angiogenesis, cell migration with tissue invasion and metastasis, inflammation induced by neoplasms, cellular energetic dysregulation and persistence in the face of immunological reaction [3,5-8].

The characterization and analysis of the described tumor cells and tissues indicate that factors that directly interfere both in some of these properties and in the phases of tumor development, are potential candidates for the production of drugs and treatments for cancer [3,5-7].

Breast cancer is the type of cancer that most affects women in the world and is also the most frequent cause of death from cancer in women (15.5% of cancer deaths in women in 2020, which corresponds to approximately 684,996 deaths, according to the International Agency for Research on Cancer (IARC) GLOBOCAN cancer statistics). In Brazil, breast cancer is the leading cause of cancer death in women, with a tendency for a higher incidence and mortality to progressively increase from the age of 40 [9,10].

Oxidative stress, an imbalance between the production and elimination of oxidants such as Reactive Oxygen Species (ROS), is a metabolic condition well characterized by medicine and its pro-oxidant imbalance is correlated with the development of degenerative and/or chronic diseases, including cancer [5,11-13]. ROS are pro-tumorigenic and tumor cell proliferation is accompanied by high ROS production [14]. Elevated levels of ROS have been identified in several types of human tumors [15].

Resveratrol (RSV), the main grape polyphenol, is also found in red fruits and red wine. Studies in rats have pointed to RSV as an important reducer of the harmful consequences of a high-fat diet, correlating it with longevity and quality of life [16,17]. This compound has attracted attention for its diverse pharmacological

properties. RSV is a potent anti-inflammatory and antioxidant capable of combating the accumulation of reactive oxidizing species and can act beneficially in metabolic conditions such as cancer, cardiovascular diseases and aging and other studies point to RSV as an agent of antioxidant activity preventive [18-21].

Therefore, we carried out a meta-analysis to better understand the antiproliferative and anti-tumorigenic effects of RSV in the phases of breast tumorigenesis.

Methods

Search strategy

We performed a computerized search out in the PubMed, ClinicalTrials.gov, Cochrane and Google Scholar databases, using the keywords *resveratrol in vivo*, *resveratrol in vivo* breast cancer, *resveratrol* in breast cancer, clinical studies with *resveratrol*, *resveratrol* and cancer, *resveratrol* and cell proliferation, *resveratrol* and anti-tumor action, antitumor mechanism of *resveratrol* and antineoplastic *resveratrol*, in English, with no cut-off limit for date to date. The search strategies were previously discussed and reviewed by the thesis author and the supervisor responsible for the research.

Study selection

The two reviewers (Trettel GD and Bertoni CRA) independently screened the titles, abstracts and full texts that were sequentially selected as eligible. Disagreements were resolved by joint review and consensus. The selection criteria were given *in vivo* in female rats and mice, comparative experiments of tumor mass before and after treatment with *resveratrol*, described in the forms of *trans-resveratrol*, *resveratrol* and synthetic analogues of *resveratrol*: HS-1793 and piceatannol, in addition to *resveratrol* as an adjuvant in synergy with other compounds known in the literature for their antioxidant and/or anti-tumor action. Duplicate publications not consistent with the theme were screened and excluded using the Rayyan tool, although, a manual search of references was performed from the beginning of the research.

Data synthesis

Data collected from preclinical studies were structured in spreadsheets and classified according to the substances used, which were distributed into four groups: RSV, RSV+hormone modulators, RSV+antioxidants and RSV+antineoplastics. The equation below was used to calculate the percentages of tumor that remained after the treatment proposed by the study (residual tumor).

$$\frac{\text{Mean treated}}{\text{Mean control}} \times 100 = \% \text{ of residual tumor}$$



Results




Figure 1: Flowchart of pre-clinical studies selected for systematic review and meta-analysis based on literature research.

Table 1: Data from preclinical studies on the use of resveratrol applied in the treatment of rodent mammary cancer. Significant difference $P < 0.05$.

Tumors treated with Resveratrol (RSV)								
Author	RSV dosage	Control		RSV Treatment		Percentage of tumor reduction	Animal age (weeks)	Probability of effect
		Tumor measurement	(N)	Tumor measurement	(N)			
Bhat et al. [22]	100 mg/kg	6	20	3.9	40	35%	5	*** $P=0.0015$
Banerjee et al. [23]	100 µg/rat	100	12	55	12	45%	4+10 days	$P<0.05$
Singletary et al. [24]	49 mg	2.5	32	1.8	43	28%	4+10 days	$P<0.05$
	65 mg			1.6		36%		
Provinciali et al. [15]	4 µg	100	49	50	49	50%	20	$P<0.02$
Garvin et al. [12]	25 mg/kg	182	5	4	5	97.80%	6 to 8	$P<0.05$
Sareen et al. [25]	50 mg/kg	630.96	36	307.62	36	51.25%	6	$P=0.003$
Schlachterman et al. [26]	0.5 mg/kg	5	10	3	10	40%	5 to 6	$P<0.05$
	5 mg/kg			1.5		70%		
	25 mg/kg			2		60%		
Wang et al. [27]	5 µg	180	10	45	20	75%	NI	*** $P<0.001$
	10 µg			30		83.33%		
Castillo-Pichardo et al. [28]	5 mg/kg RQC	100	10	63	10	37%	5 to 6	$P<0.05$
Chatterjee et al. [29]	100 µg/rat	29.1	8	21.7	8	25.43%	31	*** $P<0.001$



Pandey et al. [19]	22.4 kg/bw	13 × 10 ⁶	5	1.5 × 10 ⁶	10	88.46%	4	P<0.05
Lee et al. [30]	100 mg/kg	42.6	10	29.3	10	31.22%	5	P<0.05
	200 mg/kg			15.2		64.32%		
Lee-Chang et al. [6]	50 µg	200	15	50	15	75%	4 to 8	**P<0.01
Pandey et al. [31]	22.4 kg/bw	150	6	10	6	93.33%	3 to 4	**P<0.001
Papoutsis et al. [31]	7 ppm	100	7	50	3	50%	NI	P<0.05
Fu et al. [32]	100 mg/kg	1.5	6	0.8	6	46.67%	5	**P<0.01
Singh et al. 2014	50 mg	1086	11	545.18	6	49.80%	4	P<0.05
Kim et al. [30]	5 mg/kg	40	6	10.4	9	26%	5	*P<0.01
	10 mg/kg			28		70%		
Kisková et al. [33]	100 mg/kg	2.34	16	0.51	9	78.21%	4+1 day	**P<0.01
Lima de Silva et al. [35]	20 mg/kg	81	10	56	10	30.86%	4	P<0.001
Rossi et al. [36]	5 g/kg	364.5	15	224.8	15	38.33%	8	P<0.0001
Sun et al. [37]	40 mg/kg	0.46	8	0.1	8	78.26%	6	**P<0.01
Kim et al. [38]	0.5 mg/kg	3000	30	1500	23	50%	6	*P<0.05
	1 mg/kg			300		90%		
Peiffer et al. [39]	20 mg/kg	110	6	70	3	36.36%	8	P<0.0001

Table 2: Data from preclinical studies on the use of resveratrol associated with antioxidant compounds in the treatment of rodent mammary cancer. NI: Not informed by the author. Significant difference P<0.05.

Tumors treated with RSV+antioxidant compounds													
Author	Dose RSV	Control		RSV treatment		Antioxidant treatment		Antioxidant treatment+RSV			Percentage of tumor reduction	Animal age (weeks)	Probability of effect
		Tumor measurement	N	Tumor measurement	N	Tumor measurement	N	Tumor measurement	N	Compound			
Whitsett et al. [40]	1 g/kg	8.79	30	4.39	30	6.74	30	NI	NI	EGCG	50.06%	7	P<0.05
Vetvicka, Vetvikcova [41]	100 µg	659.7	5	380	5	230.65	5	92.26	5	Vitamin C	86.01%	8	P ≤ 0.05
Alobaedi et al. [42]	50 mg/kg	813.62	10	325.45	10	488.17	10	325.44	10	Thymoquinone	60%	6 to 8	P<0.05
García-Quiroz et al. [43]	1.2 g/kg	2.4	18	2	9	1.5	9	NI	NI	Curcumin	16.67%	6	*P<0.05
Peiffer et al. [39]	20 mg/kg	110	6	70	3	50	6	NI	NI	Naringenin/quercetin	36.36%	8	P<0.001



Table 3: Data from preclinical studies on the use of resveratrol associated with hormones in the treatment of rodent mammary cancer. NI: Not informed by the author. Significant difference P<0.05.

Tumors treated with RSV+hormonal compounds													
Author	Dosage RSV	Control		RSV treatment		Hormone treatment		Hormone treatment+RSV			Percent age of tumor reduct ion	Anim al age (wee ks)	Proba bility of effect
		Tumor measur ement	N	Tumor measur ement	N	Tumor measure ment	N	Tumor measure ment	N	Comp ound			
Kisková et al. [18]	7 mg/kg	3.11	NI	2.42	NI	3.57	NI	2.72	NI	Melat onin	12.54 %	4	P<0.0 5
Vetvicka, Vetvikcova [41]	100 µg	659.7	5	380	5	369.4	5	217.7	5	Gluca n	67%	8	P ≤ 0.05
García-Quiroz et al. [43]	1.2 g/kg	2.4	18	2	9	0.75	9	1	9	Calcitr iol	58.33 %	6	*P<0.0 5

Table 4: Data from preclinical studies on the use of resveratrol associated with antineoplastic drugs in the treatment of mammary cancer in rodents. NI: Not informed by the author. Significant difference P<0.05.

Tumors treated with RSV+antineoplastic drugs													
Author	Dosage RSV	Control		RSV treatment		Antineoplastic drugs treatment		Antineoplastic drugs treatment+RSV			Percent age of tumor reduction	Animal age (weeks)	Probabilit y of effect
		Tumor measur ement	N	Tumor measure ment	N	Tumor measu rement	N	Tumor measur ement	N	Comp ound			
Kim et al. [30]	20mg/kg	2250	5	NI	NI	1900	5	900	5	Doxorubici n	60%	6	*P<0.05
Qin et al. [44]	5 e 25 mg/kg	100	9	74	19	NI	NI	82	8	Decita bine	18%	7	P<0.05
Meng et al. [45]	20 mg/kg	100	3	74.19	3	22.18	3	9	3	Paclit axel	91%	2	P<0.05
Yang et al. [46]	100 mg/kg	0.5	5	0.4	10	0.25	10	0.2	10	Cispla tin	60%	7	*P<0.01
Bellare & Patro [47]	50 mg/kg	4000	5	1800	5	2100	5	900	5	Talaz opari b	77.50%	6	***P<0.001




Figure 2: Forest-plot of the percentage of residual mammary tumor in female rodents after treatment with resveratrol, combined or not with other substances.



Table 5: Characteristics of clinical studies with resveratrol or trans-resveratrol in patients diagnosed with breast cancer. HD: high-dose T-RSV/LD: Low-dose TRSV/PE: Physical exercise/HER2: Human epidermal growth factor receptor type 2/Metastasis: MX-M0/NI: Not informed by the author / PgR: Progesterone receptor/ER: Estrogen receptor/Nodal status: N0-N1/TNM: Size of solid tumors in cm (T1-T4)/T-RSV: Trans-resveratrol/#: Median/*: Tumor type.

Author Year	Country	Follow-up (months)	Number of patients		Age (mean $\pm$ SD)		Clinicopathological features
			Control	Treated	Control	Treated	
Levi F, et al. [48]	Canton of Vaud, Switzerland	3	602	369	23-74 years; 59#	23-74 years; 59#	Diagnosis of breast cancer in the previous year, histologically confirmed
Miksits M, et al. [49]	Viena, Áustria	NI	13	13	59.9 $\pm$ 7.8	59.9 $\pm$ 7.8	TNM, HER2, ER, PgR *Ductal, lobular, mucinous type
DiFranco R, et al. [14]	Itália (regions of Naples, Avellino, Florence and Salerno)	8	41	30	59,71 $\pm$ 9.92	52,10 $\pm$ 11,26	*Ductal, lobular, mucinous type Chemotherapy, hormone therapy, breast volume
Zhu W, et al. [50]	North Dakota, EUA	3	9	21	61#	59.5 LD 54 HD	1 st degree family history of breast cancer, Gail's risk >1.66% of developing cancer within 5 years and/or personal history of biopsy showing atypical hyperplasia <i>in-situ</i> or invasive breast cancer previously treated and currently free from disease
Ávila-Gálvez MA, et al. [23]	Murcia, Espanha	6	8	19	56 $\pm$ 10	56 $\pm$ 10	TNM, nodal status, metastasis HER2, ER, PgR *Ductal, lobular, mucinous, other type
Filgueira TO [52]	Pernambuco, Brazil	3+14 days	36	36	Control 54 $\pm$ 12 PE+ placebo 55 $\pm$ 9	PE+RSV 51 $\pm$ 8 RSV 58 $\pm$ 11	Post-menopause, completion of adjuvanted chemotherapy, sedentary lifestyle

Table 6: Data on the effects of resveratrol and trans-resveratrol in clinical studies conducted between 2005 and 2019. CG: Control group/Ext: Extract/glucuronide: RSV metabolite/IG: Treated group (Ixor®)/OR: Chance ratios/PGE2: Prostaglandin E2/PTV: Margin of variations and errors associated with treatment/RASSF1a: Tumor suppressor gene/SULT1A2: Sulfotransferase/Th17: Pro-inflammatory helper T cells.

Author year	RSV or T-RSV dosage	Analysis	Odds ratio
Levi F, et al. [48]	Estimated intake by frequency of consumption (total number of glasses per week) of white wine (70 ml) and red wine (125 ml) and grapes (standard portions of 230 g)	Relationship between dietary resveratrol intake and breast cancer using data from a case control study	OR for resveratrol from grapes=0.64 and 0.55
Miksits M, et al. [49]	1 μ M 0.5-100 μ M in specific samples (5, 8 and 9)	Resveratrol metabolism in breast cancer tissue and adjacent non-cancerous tissue Expression of sulfation enzymes	Higher resveratrol sulfation in 12/13 cancerous tissue samples (p<0.001) Higher SULT1A2 expression in cancerous tissue p < 0.0002 Higher STS mRNA expression in 12/13 non-malignant samples (p<0.0017)
DiFranco R, et al. [14]	2 tablets/day 10 days pre and post radiation treatment	Effect of antioxidants rsv, lycopene, vitamin C and anthocyanins (Ixor®) in reducing skin toxicity due to radiotherapy in breast cancer patients	CG $\times$ IG (high PTV): OR 0,77 CG $\times$ IG (low PTV): OR 0,23 CG $\times$ IG (chemo+anthracyclines and taxanes): OR 0.68



Zhu W, et al. [50]	Placebo: 0mg T-RSV: 5 mg and 50 mg	Relationship between resveratrol concentration and DNA methylation and PGE2 alteration RASSF-1α methylation	Increased T-RSV and glucuronide: P<0.001 Decreased RASSF-1α methylation (P=0.047) directly related to change in PGE2 (P=0.045)
Ávila-Gálvez MA, et al. [23]	Capsule (700 mg) with: 53.85 mg T-RSV/161.5 mg pomegranate ext/53.85 mg orange ext/53.85 mg lemon ext/161.5 mg olive ext/161.5 mg cocoa ext/53.85 mg grape seed ext	Metabolic profile of dietary phenolics and methylxanthines and their derivatives in biological samples Estrogenic and antiestrogenic activities	*P<0.05
Filgueira TO, [52]	500 mg daily of RSV	Analysis of chronic inflammatory process in response to physical exercise and use of RSV Analysis of the modulation of serum levels of pro- and anti-inflammatory cytokines and the Th17 pattern Analysis of anthropometric parameters, body composition and physical fitness using RSV	Physical exercise+RSV: Reduction in serum concentration of cytokine IL17A, p=0.024

Discussion

According to the data presented in **tables 1,2,3,4,5 and 6** the results indicated that the use of RSV as the main treatment in rodents with breast cancer reduced tumors in at least 85% of the cases analyzed, with 34 studies showing positive and beneficial effects of the RSV as an antitumor agent, among the 40 studies that fit into our methodological analysis.

The data presented in **Table 1** show that RSV delayed the appearance of breast tumors induced by Nitroso-Methyl-Urea (NMU) and suppressed their incidence in the first days of treatment, an effect that suggests greater efficacy in early stages, when there are possibly hyperplastic lesions. and smaller premalignant in the mammary gland and with a more pronounced response on the ERs. RSV also inhibited the formation of atypical ductal hyperplasia induced by 7-12, Dimethylbenzanthracene (DMBA) promoted by 17 β-estradiol (E2), data that, in association with previous works reported in the literature, suggest RSV as a new Selective Estrogen Receptor Modulator (SERM) [22,25,26,29,38,53,54].

It was observed that NFκB activation induced by Tumor Necrosis Factor (TNFs) type pro-inflammatory cytokines was suppressed in the majority of animals treated with RSV through the increase in recombinant NFκB Inhibitory protein (IK-Bα). Therefore, the downregulation of NFκB suggests that RSV may attenuate the initial steps of tumor development including dysregulation of proliferation control and protection against apoptosis of healthy cells [23,28].

Analyzes of RSV and its analog piceatannol in Welch Concord grape juice, *in vivo*, demonstrate significant inhibition of tumor multiplicity and mass in rat breasts, indicating possible inhibition of the promotion phase of tumorigenesis. There was a significant reduction in DNA

synthesis of the adenocarcinoma cell line isolated from rat breast induced by DMBA and inhibition of tyrosine kinase signaling cascades [3,14,24,55-57].

RSV supplementation showed antitumor effects by delaying the development and metastatic capacity of tumors in HER-2/neu transgenic mice, an effect associated with downregulation of HER-2/neu expression and consequent apoptosis of mammary tumor cells [15,58].

The results obtained by Garvin (2006) corroborate other studies that point to the chemotherapeutic potential of RSV [12]. The data obtained indicate that the anti-tumor effects of RSV may be due to the synergism between the induction and significant increase in apoptosis in tumors treated with the antioxidant, in addition to the inhibition of angiogenesis through Vascular Endothelial Growth Factor (VEGF) at extracellular levels. It is well established that RSV is a potent Sirtuin 1 (SIRT1) agonist, responsible for regulating transcriptional activation and apoptosis associated with the tumor suppressor gene p53 [27,40,59, 60].

Another consolidated effect of RSV and shown in the results of our meta-analysis is its action as a potent competitive inhibitor of 5-LOX activity [19,29,31,36]. RSV is certainly capable of inhibiting the proliferation of cancer stem cells *in vivo*. Experiments demonstrated that RSV treatment suppressed the expression of Fatty Acid Synthase (FAS) and strongly increased pro-apoptotic genes cell Death-Associated Protein Kinase 2 (DAPK2) and Bcl-2-Interacting Protein 3 (BNIP3) [19].

The high expression of Metalloproteinase-9 (MMP-9), an enzyme that degrades components of the extracellular matrix, is strongly associated with the worsening of the invasive potential of breast cancer cells. Studies showed that RSV suppressed tumor progression by inhibiting the



expression of MMP-9 and pro-inflammatory mediators such as TNF- α , Interleukin 1 beta (IL-1 β), Cyclooxygenase 2 (COX-2) and induced Nitric Oxide Synthase (iNOS) [25,37,61].

Data from Lee et al (2012) showed this inhibition of MMP-9 mRNA in 4T1 cell lines by RSV, in addition to the fact that its oral administration inhibited cancerous cell growth and/or prevented its lung metastasis [30].

During pregnancy in rodents, exposure to Aryl hydrocarbon Receptor (AhRR) antagonists, such as RSV may exert protective effects against the development of breast tumors in the newborn. Pretreatment with RSV antagonizes the effects of the carcinogenesis inducer Tetrachlorodibenzene (TCDD) on the expression of BRCA-1, Cytochrome P450 family 1 (CYP1A1) and Cyclin-Dependent Kinase 4 (CDK4) protein, in addition to increasing the occupancy of sites of BRCA-1 by AhRR [32,35].

HS-1793, a synthetic analogue of RSV, significantly inhibited breast tumor growth, proliferation and formation of tumor vessels, in a dose-dependent manner, with greater efficacy than RSV [61].

RSV stimulates autophagy in breast Cancer Stem Cells (CSCs) by suppressing the Wnt/b-catenin pathway *in vitro* and *in vivo* [33].

Data from animals treated with RSV in association with antioxidants suggest modulatory effects of EGCG on the structure of the mammary gland induction of selective apoptosis, reduction of tumor cell disorder, increase in the quantity and activity of CD4+ and CD8+ T cells in the spleen and tumor atmosphere of mice carriers of 4T1 breast tumor [62,63].

RSV associated with vitamin C triggers a significant increase in phagocytosis in addition to reducing the growth of cancer cells, possibly by stimulating the activity of NK cells, reducing the levels of C-reactive protein and pro-inflammatory cytokines, delaying the metastatic process and tumor growth, increased tumor encapsulation and cellular protection against lipid peroxidation [41,64]. Thymoquinone (active compound from *Nigella sativa* L) in combination therapy with RSV reduced tumor measurements by approximately 60%, inducing necrosis of the tumor area, apoptosis and inhibition of angiogenesis by decreasing VEGF expression, without liver or kidney toxicity [42].

Curcumin (Cur), an active compound from the *Curcuma longa* root, is studied for its antiproliferative, pro-apoptotic, antioxidant and inhibitory effects on tyrosine kinase activity. *In vivo* and *in vitro* studies point to curcumin as a possible inhibitor of Receptor Tyrosine Kinase (RTK) receptors, in addition to the ability to consistently reduce the diameter of tumor vessels in mice Xeno transplanted with TNBC cells, when in synergy with calcitriol and RSV. Other analyzes suggest that one of the

most relevant antitumorigenic effects of curcumin was the inhibition of neoangiogenesis and reduction of the expression of the β 3 subunit integrin (Itgb3) [43].

Data using the flavanone naringenin, easily found in citrus fruits (mainly orange peel), showed blockade of (TGF)- β 1 in breast cancer cells and suppression of lung metastasis by inhibition of PKC protein activation in addition to regulation of mitochondrial apoptosis and p53 [49,50,65-71]. Associated with RSV, selective action on alpha and beta estrogen receptors (ER α and ER β) was noted [39,64,68].

The combination of polyphenols such as RSV and quercetin decreased cell proliferation and arrested the G2/M phase selectively in breast cancer cells, suggesting such compounds as potent inhibitors of cell proliferation [3,50,48]. In addition to quercetin, the antioxidant catechin, both when associated with RSV, demonstrated a reduction in the expression of the AKT1 pathway and can increase the levels of forkhead proteins (FOXO1), which has shown an important association with the anticancer activities of RSV [3,10,48].

The association of the hormonal modulator glucan with RSV showed a potent synergistic action on the antitumor action mechanisms of these compounds, as well as strong stimulation of immune reactions [61,65].

Calcitriol (Cal), an active metabolite of vitamin D, is considered a multitarget anticancer hormone and explored in pharmacological doses as an oncological drug. The data indicate a broad reduction in volume and microvascular density in animals treated with Cal+Curcumin and Cal+RSV, in addition to a reduction in the activation of the tumor endothelium due to a decrease in the tumor absorption of integrin-directed biosensors *in vivo*, suggesting a notable biological effect of inhibition. of tumor neoangiogenesis [49].

Melatonin acts as a SERM modulator just like RSV, preventing the proliferation of cancer cells and negatively regulating estrogen-synthesizing enzymes such as aromatase [18]. Prolonged administration of RSV associated with melatonin significantly reduces the number of invasive carcinomas and tumor incidence. These data suggest that at pharmacological doses the antioxidant effects of melatonin, when associated with RSV, can suppress breast tumors by inhibiting growth factors [18,33].

The antineoplastic drug Doxorubicin (Dox), despite stimulating the production of ROS, is widely used in the treatment of metastatic breast cancer and is an important clinical problem that causes treatment failure and abandonment [69].

Dox and RSV showed a synergistic effect in inhibiting the proliferation of breast tumor cells, significantly



reducing tumor volume by approximately 50%. Given this result, the researchers indicated that RSV possibly exerts this effect in relation to drug transport through several pathways, such as mediating the expression of ATP-Binding Cassette (ABC), NF-K β , COX2, CYP3A4 and ROS transporters and by inhibition of MDR1 and MRP1. These data suggested that RSV may increase the efficacy of dox and be beneficial for overcoming drug resistance [54].

Decitabine (AZA) activates tumor suppression genes and cellular senescence followed by apoptosis. Studies with AZA and RSV showed that 82% of rats treated with RSV and AZA did not develop mammary tumors, while in animals treated with AZA alone, only 67% did not develop tumors [44]. RSV and AZA upregulated tumor suppressor miRNAs (miR21) in breast tumor tissue but not in physiological breast tissue, which may be an additional mechanism by which RSV suppresses tumor development and progression [44].

Researchers constantly aim to develop strategies to alleviate drug resistance during cancer treatment. RSV and PTX were co-encapsulated in a liposome in order to reverse PTX resistance of MCF-7/Adr tumors and amplify the efficacy of both components *in vivo*. These results demonstrate more potent synergistic tumor inhibition action and a direction that a nanocarrier may have potentially essential applications for the treatment of drug-resistant neoplasms [45].

Cisplatin has antitumor activity attributed to covalent binding to DNA, inducing structural changes, inhibiting cell growth, transcription and replication, resulting in apoptosis. *In vitro* and *in vivo* studies on MDA231 xenografts with RSV and cisplatin show increased tumor growth inhibition, in addition to reduced body weight loss and impaired renal function caused by cisplatin. These data indicate that RSV sensitizes the effects of cisplatin by inhibiting cell migration and invasion, reducing the expression of vimentin, fibronectin and increasing the expression of E-cadherin, indicating efficacy in reversing EMT [46,72].

The drug talazoparib is an inhibitor of PARP, a DNA repair protein that, when silenced, results in tumor cell death. Recent studies have explored a dual action of RSV, which consists of inhibition of phosphorylation of the AKT pathway and induction of autophagy and death of breast cancer cells, *in vitro* and *in vivo*, which is attributed to its effect on PARP mediated by talazoparib (BMN673) [47].

The combined oral administration of RSV+talazoparib significantly reduced the growth of mammary tumors in mice [47]. These data also indicate a therapeutic approach for other potential PARP inhibitors in oncological treatments.

In clinical studies, qualitative data have shown that resveratrol from grapes and wine is inversely related to

breast cancer risk, although the presence of alcohol in the same model may affect collinearity (Pearson's correlation coefficient between total alcohol intake and resveratrol, $r=0.85$). The positive data found for the response of resveratrol to breast tumorigenesis were directed to its already known mechanisms of action, such as apoptosis, cellular control, anti-inflammatory and hormonal effects [48].

In human breast cancer cells (MDAMB-231 and ZR-75-1), RSV is metabolized to resveratrol-3-O-sulfate by the expression of SULT1A1 and in smaller quantities, by SULT1A2, SULT1A3 and SULT1E1. This metabolization is significantly greater in tumor tissue than in adjacent non-malignant samples from the same patients [49].

The experiments performed showed that in control tissue samples there was expression of Steroid Sulfatases (STS), responsible for increased tumor cell proliferation, while the same was not observed in samples treated with RSV [49]. Therefore, the use of RSV may be a targeted therapy in the inhibition of this enzyme, a promising strategy in the treatment of breast cancer and/or with combined therapies.

One of the adverse effects of radiotherapy is skin toxicity, especially in high doses, so research is seeking treatments to alleviate this discomfort. The radioprotective effect of resveratrol was evaluated together with the antioxidant's lycopene, vitamin C and anthocyanins (Ixor® supplement) in reducing skin toxicity in patients with breast cancer who underwent chemotherapy with anthracyclines and taxanes. Data showed that RSV acts by inhibiting the production of IL-8, interrupting the phosphorylation of MAPK and NF κ B, preventing damage caused by UVB radiation and thus improving the radiosensitivity of tumor cells. Other studies also associate the anticancer effects of RSV with the induction of apoptosis and activation of pro-apoptosis genes: FAS, p-53 and p21 [50].

Methylation of the tumor suppressor gene RASSF1a is triggered and stimulated as breast cancer progresses. The dose-dependent effects of resveratrol on DNA methylation in women at risk for breast cancer were evaluated in a double-blind, placebo-controlled study. Despite the limited sample size, the data show that chronic administration of the trans-resveratrol isomer increases its circulating levels, as well as its glucuronide metabolite. Note that this administration also prevented RASSF-1a methylation and PGE2 expression in the breast, revealing a novel mechanism for the chemo preventive effect of trans resveratrol in women at high risk for breast cancer [51].

Methylxanthine alkaloids (MX), central nervous system stimulants, can increase the bioavailability of flavanols and studies seek to elucidate whether polyphenols and MX can act directly on Malignant breast Tissues (MT), since the *in-situ* conjugation/deconjugation process depends on the tissue microenvironment. The chemo preventive effects of



MX were related to the inhibition of the poly nuclear adenosine diphosphate ribose polymerase-1 enzyme and the downregulation of Breast Cancer Resistance Proteins (BCRP/ABCG2) [52].

Such evidence may be used to improve the efficacy of antineoplastic drugs that are substrates of breast cancer-resistant proteins (ATP-binding cassette, subfamily G, member 2: ABCG2) and also to sensitize tumor cells to respond to chemotherapeutic drugs, such as tamoxifen, impairing the growth of breast tumors. Normal Tissues (NT) and MT from breast cancer patients were applied, investigating whether concentrations and molecular isoforms of metabolites exert antiproliferative, estrogenic and/or antiestrogenic effects in these tissues. Metabolite sulfation was higher in MT due to increased sulfation activity in breast tumor cells. Increased plasma concentration of unconjugated resveratrol was associated with abnormal absorption of RSV V.O by interaction between Lipopolysaccharide (LPS) transporters and ATP-Binding Cassette (ABC) transmembrane proteins. Previous studies have shown that oral resveratrol sulfate in humans could form an intracellular reservoir of resveratrol [52].

A randomized and blinded clinical study conducted at the Hospital das Clínicas of the Federal University of Pernambuco (UFPE) investigated the relationship between home-based physical exercise and resveratrol in relation to the chronic inflammatory process in breast cancer survivors. The combination of exercise + RSV was effective in increasing cardiorespiratory fitness and modulating systemic levels of pro-inflammatory cytokines, reducing the cytokine IL-17A, while RSV alone only showed a modulatory action, reducing the cytokine IL-17A [53]. Therefore, we can consider that resveratrol has important effects for breast cancer therapy, which can be enhanced by several factors, such as the combined action of drugs, physical exercise and synergy with other antioxidants, in addition to a routine of healthy habits.

Conclusions

In *in vivo* studies, RSV delayed the appearance of carcinogen-induced breast tumors, suppressing tumor incidence in the initial days of treatment. Besides, it attenuated the activation of pro-inflammatory mediators, inhibited the proliferation of cancer stem cells by stimulating autophagy and promoted mitochondrial apoptosis so as to consistently reduce tumor diameter, volume and neoangiogenesis. It showed a synergistic effect with antineoplastic drugs, positively regulating tumor suppressor miRNAs in breast tumor tissue, preventing tumor progression and resistance to these drugs; It amplified its own effectiveness and that of antineoplastic drugs when co-encapsulated in a liposome.

After a systematic review and meta-analysis, it was possible to significantly advance the understanding of the beneficial role of resveratrol in the tumor microenvironment of breast cancer, showing how

resveratrol can act on the stages of the carcinogenesis process, in addition to mapping the possible mechanisms involved in this action, expanding therapeutic targets to be explored as a treatment for breast cancer. The data found in the literature consistently presented the preventive role of resveratrol in several diseases, especially those whose biogenesis is associated with oxidative stress, as well as its importance for maintaining and promoting health as a whole.

References

1. Collaço PMC, Larissa E; Silva, Suely CT (2019) Incidence of neoplasia according to sex, in Brazil, in 2018. *Journal of Health & Science Online* 8: 79-85.
2. Hanahan D, Weinberg R (2011) Hallmarks of cancer: The next generation. *Cell* 144: 646-674. [Crossref] [Google Scholar] [Indexed]
3. Hayes JD, Albena TDK, Kenneth DT (2020) Oxidative stress in cancer. *Cancer Cell* 38: 167-197. [Crossref] [Google Scholar]
4. Trettel G, Bertoncini CRA (2020) Application of lavender in integrative medicine: From aromatherapy to potential anticancer treatment. *Clinics in Oncology* 5: 1740.
5. Gottlieb MG, et al. (2010) Oxidative stress as an emerging cardiometabolic risk factor. *Scientia Medica* 20: 243-249.
6. Lee-Chang C, et al. (2013) Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory b cells. *J Immunol* 191: 4141-4151. [Crossref] [Google Scholar] [Indexed]
7. Marçola M, Rodrigues CE (2015) Endothelial progenitor cells in tumor angiogenesis: Another brick in the wall. *Stem Cells International*: 10. [Crossref] [Google Scholar] [Indexed]
8. Nahed S, Shaimaa Y (2016) Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer Biology & Medicine* 13: 496. [Crossref] [Google Scholar] [Indexed]
9. Ferlay J, et al. (2021) Cancer statistics for the year 2020: An overview. *International journal of cancer* 149: 778-789. [Crossref] [Google Scholar] [Indexed]
10. Joseph National Cancer Institute (INCA) (2019) Ministry of Health (Ms). Estimate 2020: Non-Brazil cancer incidence. Rio de Janeiro: Brazil: 120.
11. Bertoncini CRA, et al. (2016) Preferential localization of iron in the chromatin of Fe-Enriched cells is linked to DNA cleavage sites and control of carcinogenesis. *Journal of Cancer Science and Therapy* 8: 213. [Crossref] [Google Scholar]
12. Garvin S, Ollinger K, Dabrosin C (2006) Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts *in vivo*. *Cancer Lett* 231: 113-122. [Crossref] [Google Scholar] [Indexed]
13. Silva CT, Jasiulionis MG (2014) Relationship between oxidative stress, epigenetic alterations and cancer. *Cienc Cult*



14. Gunther S, et al. (2006) Polyphenols prevent cell shedding from mouse mammary cancer spheroids and inhibit cancer cell invasion in confrontation cultures derived from embryonic stem cells. *Cancer Lett* 250: 25-35. [Crossref] [Google Scholar] [Indexed]
15. Provinciali M, et al. (2005) Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. *Int J Cancer* 115: 36-45. [Crossref] [Google Scholar] [Indexed]
16. Carbó N, et al. (1999) Resveratrol, a natural product presented in wine, decreases tumour growth in a rat tumour model. *Biochem Biophys Res Commun* 254: 739-743. [Crossref] [Google Scholar] [Indexed]
17. Dayem AA, et al. (2016) The anti-cancer effect of polyphenols against breast cancer and cancer stem cells: Molecular mechanisms. *Nutrients* 8: 581. [Crossref] [Google Scholar] [Indexed]
18. Kisková T, et al. (2012) A combination of resveratrol and melatonin exerts chemo preventive effects in N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. *Eur J Cancer Prev* 21: 163-170. [Crossref] [Google Scholar] [Indexed]
19. Pandey P, et al. (2011) Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. *Breast Cancer Res Treat* 130: 387-398. [Crossref] [Google Scholar] [Indexed]
20. Pannu N, Bhatnagar A (2019) Resveratrol: From enhanced biosynthesis and bioavailability to multitargeting chronic diseases. *Biomedicine & Pharmacotherapy* 109: 2237-2251. [Crossref] [Google Scholar] [Indexed]
21. Polonio NCV, et al. (2014) Trans-resveratrol concentrations and antimutagenic potential of juice from the grape cultivars Vênus, BRS Violeta and Isabel. *Genetics and Molecular Research* 13: 1152-1159. [Crossref] [Google Scholar] [Indexed]
22. Bhat K, et al. (2001) Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. *Cancer Res* 61: 7456-7463. [Google Scholar] [Indexed]
23. Ávila-Gálvez MA, et al. (2019) Metabolic profiling of dietary polyphenols and methylxanthines in normal and malignant mammary tissues from breast cancer patients. *Mol Nutr Food Res* 63: e1801239. [Crossref] [Google Scholar] [Indexed]
24. Singletary K, Meline B (2003) Effect of grape seed proanthocyanidins on colon aberrant crypts and breast tumors in a rat dual-organ tumor model. *Nutr Cancer* 39: 252-258. [Crossref] [Google Scholar] [Indexed]
25. Sareen D, et al. (2007) Mitochondria, calcium and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. *Mol Pharmacol* 72: 1466-1475. [Crossref] [Google Scholar] [Indexed]
26. Schlachterman A, et al. (2008) Combined resveratrol, quercetin and catechin treatment reduces breast tumor growth in a nude mouse model. *Transl Oncol* 1: 19-27. [Crossref] [Google Scholar] [Indexed]
27. Wang RH, et al. (2008) Interplay among BRCA1, SIRT1 and Survivin during BRCA1-associated tumorigenesis. *Mol Cell* 32: 11-20. [Crossref] [Google Scholar] [Indexed]
28. Castillo-Pichardo L, et al. (2009) Inhibition of mammary tumor growth and metastases to bone and liver by dietary grape polyphenols. *Clin Exp Metastasis* 26: 505-516. [Crossref] [Google Scholar] [Indexed]
29. Chatterjee M, et al. (2011) Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz (α) anthracene-induced mammary carcinogenesis in rats. *Eur J Pharmacol* 668: 99-106. [Crossref] [Google Scholar] [Indexed]
30. Lee HS, Wha HA, Kim WK (2012) Effect of resveratrol on the metastasis of 4T1 mouse breast cancer cells *in vitro* and *in vivo*. *Nutrition Research and Practice* 6: 294. [Crossref] [Google Scholar] [Indexed]
31. Pandey P, et al. (2019) Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma *in-situ* of breast cancer. *Oncogene* 32: 5111-5122. [Crossref] [Google Scholar] [Indexed]
32. Papoutsis A, et al. (2013) Gestational exposure to the AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin induces BRCA-1 promoter hypermethylation and reduces BRCA-1 expression in mammary tissue of rat offspring: Preventive effects of resveratrol. *Mol Carcinog* 54: 261-269. [Crossref] [Google Scholar] [Indexed]
33. Yujie FU, et al. (2014) Resveratrol inhibits breast cancer stem-like cells and induces autophagy *via* suppressing Wnt/β-catenin signalling pathway. *PLoS One* 9: e102535. [Crossref] [Google Scholar] [Indexed]
34. Kisková T, et al. (2017) Nocturnal resveratrol administration inhibits chemically induced breast cancer formation in rats. *J Physiol Pharmacol* 68: 867-875. [Google Scholar] [Indexed]
35. DeLima ES, Tassia C, et al. (2017) Maternal resveratrol treatment reduces the risk of mammary carcinogenesis in female offspring prenatally exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Hormones and Cancer* 8: 286-297. [Crossref] [Google Scholar] [Indexed]
36. Rossi E, et al. (2018) Resveratrol inhibits obesity-associated adipose tissue dysfunction and tumor growth in a mouse model of postmenopausal claudin-low breast cancer. *Mol Carcinog* 57: 393-407. [Crossref] [Google Scholar] [Indexed]
37. Sun Y, et al. (2019) Resveratrol Inhibits the migration and metastasis of MDA-MB-231 human breast cancer by reversing TGF-β1-induced epithelial mesenchymal transition. *Molecules* 24: 1131. [Crossref] [Google Scholar] [Indexed]



38. Kim JS, et al. (2020) The resveratrol analogue, HS-1793, enhances the effects of radiation therapy through the induction of anti-tumor immunity in mammary tumor growth. *International Journal of Oncology* 56: 1405-1416. [Crossref] [Google Scholar] [Indexed]
39. Peiffer D, et al. (2020) DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor development. *npj Breast Cancer* 6: 37. [Crossref] [Google Scholar] [Indexed]
40. Whitsett T, Carpenter M, Lamartiniere C (2006) Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. *Journal of Carcinogenesis* 5: 15. [Crossref] [Google Scholar] [Indexed]
41. Vetvicka V, Vetvickova J (2012) Combination of glucan, resveratrol and vitamin c demonstrates strong anti-tumor potential. *Anticancer Research* 32: 81-88. [Google Scholar] [Indexed]
42. Alobaedi O, Talib W, Basheti I (2017) Antitumor effect of thymoquinone combined with resveratrol on mice transplanted with breast cancer. *Asian Pac J Trop Med* 10: 400-408. [Crossref] [Google Scholar] [Indexed]
43. García-Quiroz J, et al. (2019) Synergistic antitumorigenic activity of calcitriol with curcumin or resveratrol is mediated by angiogenesis inhibition in triple negative breast cancer xenografts. *Cancers* 11: 1739. [Crossref] [Google Scholar] [Indexed]
44. Qin W, et al. (2014) Methylation and miRNA effects of resveratrol on mammary tumors vs. normal tissue. *Nutrition and Cancer* 66: 270-277. [Crossref] [Google Scholar] [Indexed]
45. Meng J, et al. (2016) Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells *in vivo*. *Sci Rep* 6: 22390. [Crossref] [Google Scholar] [Indexed]
46. Yang MD, et al. (2021) Resveratrol enhances inhibition effects of cisplatin on cell migration and invasion and tumor growth in breast cancer MDA-MB-231 cell models *in vivo* and *in vitro*. *Molecules* 26: 2204. [Crossref] [Google Scholar] [Indexed]
47. Bellare P, Patro S (2022) Resveratrol sensitizes breast cancer to PARP inhibitor talazoparib through dual inhibition of AKT and autophagy flux. *Biochem Pharmacol* 199: 115024. [Crossref] [Google Scholar] [Indexed]
48. Levi F, et al. (2005) Resveratrol and breast cancer risk. *Eur J Cancer Prev* 139-142. [Crossref] [Google Scholar] [Indexed]
49. Miksits M, et al. (2010) Expression of sulfotransferases and sulfatases in human breast cancer: Impact on resveratrol metabolism. *Cancer Lett* 289: 237-245. [Crossref] [Google Scholar] [Indexed]
50. DiFranco R, et al. (2012) Skin toxicity from external beam radiation therapy in breast cancer patients: Protective effects of resveratrol, lycopene, vitamin c and anthocianin (Ixor®). *Radiation Oncology* 7: 12. [Crossref] [Google Scholar] [Indexed]
51. Zhu W, et al. (2012) Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. *Nutrition and Cancer*. [Crossref] [Google Scholar] [Indexed]
52. Tae-Hyung K, et al. (2014) Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells *via* increased cellular influx of doxorubicin. *Biochimica et Biophysica Acta* 1840: 615-625. [Crossref] [Google Scholar] [Indexed]
53. Filgueira TO (2019) Effect of resveratrol combined with home-based physical exercise on inflammatory profile and physical fitness in breast cancer survivors: Randomized, blinded clinical trial. *Federal University of Pernambuco*.
54. Banerjee S, Bueso-Ramos C, Aggarwal B (2002) Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor- κ B, cyclooxygenase 2 and matrix metalloprotease 9. *Cancer Res* 62: 4945-4954. [Google Scholar]
55. Bhupendra, et al. (2014) Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways. *Carcinogenesis* 35: 1872-1880. [Crossref] [Google Scholar] [Indexed]
56. Hecht S, et al. (1999) Evaluation of butylated hydroxyanisole, myoinositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. *Cancer Lett* 137: 123-130. [Crossref] [Google Scholar]
57. Jang M, Pezzuto J (1998A) Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin. *Cancer Lett* 134: 81-89. [Crossref] [Google Scholar] [Indexed]
58. Tessitore L, et al. (2000) Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 CIP expression. *Carcinogenesis* 21: 1619-1622. [Crossref] [Google Scholar] [Indexed]
59. Lara RC (2018) Oxidative stress: *In vitro* evaluation of the modulatory capacity of resveratrol in neuro 2-a lineage cells]. 95 f. thesis (Doctorate in Neurosciences)-Laboratory of biochemistry and immunology of aging and related skills. *Federal University of Minas Gerais: Belo Horizonte*. [Google Scholar]
60. Ferraz DC, Danielly, et al. (2020) Resveratrol prevents p53 aggregation *in vitro* and in breast cancer cells. *Oncotarget* 9: 29112-29122. [Crossref] [Google Scholar] [Indexed]
61. Xu RY, et al. (2019) Resveratrol attenuates myocardial hypoxia/reoxygenation-induced cell apoptosis through DJ-1-mediated SIRT1-p53 pathway. *Biochemical and biophysical research communications* 514: 401-406. [Crossref] [Google Scholar]



Scholar] [Indexed]

62. Dong-Hwan K, et al. (2017) HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. *International Journal of Oncology* 51: 715-723. [Crossref] [Google Scholar] [Indexed]
63. Bimonte S, et al. (2020) Current shreds of evidence on the anticancer role of EGCG in triple negative breast cancer: An update of the current state of knowledge. *Infectious agents and cancer* 15: 1-6. [Crossref] [Google Scholar] [Indexed]
64. Xu P, et al. (2020) Green tea polyphenol EGCG attenuates MDSCs-mediated immunosuppression through canonical and non-canonical pathways in a 4T1 murine breast cancer model. *Nutrients* 12: 1042. [Crossref] [Google Scholar] [Indexed]
65. Mata AMOF, et al. (2016) Ascorbic acid in the prevention and treatment of cancer. *Revista da Associação Médica Brasileira* 62: 680-686. [Crossref] [Google Scholar] [Indexed]
66. Pateliya B, Burade V, Goswami S (2021) Enhanced antitumor activity of doxorubicin by naringenin and metformin in breast carcinoma: An experimental study. *Naunyn-Schmiedeberg's Archives of Pharmacology* 394: 1949-1961. [Crossref] [Google Scholar] [Indexed]
67. Zhao Z, et al. (2019) Naringenin inhibits migration of breast cancer cells *via* inflammatory and apoptosis cell signalling pathways. *Inflammopharmacology* 27: 1021-1036. [Crossref] [Google Scholar] [Indexed]
68. Wu L, et al. (2021) Antitumor effect of soluble β -glucan as an immune stimulant. *Int J Biol Macromol* 179: 116-124. [Crossref] [Google Scholar] [Indexed]
69. Gatto M, Mota G (2021) Influence of doxorubicin treatment on heme metabolism in cardiomyoblasts: An *in vitro* study. *Arq Bras Cardiol* 116: 323-324. [Crossref] [Google Scholar] [Indexed]
70. Yang X, et al. (2019) The role and mechanism of SIRT1 in resveratrol-regulated osteoblast autophagy in osteoporosis rats. *Scientific reports* 9: 1-15. [Crossref] [Google Scholar] [Indexed]
71. Jang M, Pezzuto J (1999B) Cancer chemo preventive activity of resveratrol. *Drugs Exp Clin Res* 25: 65-77.
72. Zhang T, et al. (2018) Cytotoxicity-guided isolation of two new phenolic derivatives from *Dryopteris fragrans* (L.) Schott. *Molecules* 23: 1652. [Crossref] [Google Scholar] [Indexed]